{"id":3967,"date":"2023-06-18T14:22:27","date_gmt":"2023-06-18T14:22:27","guid":{"rendered":"https:\/\/www.english-culture.com\/?p=3967"},"modified":"2025-08-21T14:23:17","modified_gmt":"2025-08-21T14:23:17","slug":"teva-pharmaceutical-industries","status":"publish","type":"post","link":"https:\/\/www.english-culture.com\/teva-pharmaceutical-industries\/","title":{"rendered":"Teva Pharmaceutical Industries"},"content":{"rendered":"
\"Teva<\/a>
Teva Pharmaceutical Industries<\/figcaption><\/figure>\n

Teva Pharmaceutical Industries, a very good stock for traders and investors looking for a real good investment for the future, at least we hope so. Last news about TEVA.<\/a>
\n<\/span><\/p>\n

https:\/\/www.drugdiscoverytrends.com\/teva-launches-first-generic-glp1-drug-us-market\/<\/span><\/a><\/p>\n

Teva readies first generic version of GLP-1 drug Victoza in U.S. Generic giant Teva Pharmaceuticals will launch the first generic version of Victoza (liraglutide injection 1.8mg) in the U.S, making it the first generic GLP-1 drug to enter the U.S. market. The patent for Novo Nordisk\u2013developed liraglutide is set to expire until November 18, 2024. Other popular GLP-1 drugs, such as semaglutide (marketed as Ozempic and Wegovy), still maintain patent protection until 2026. Victoza had annual sales of $1.656 billion as of April 2024. \u201cWe are pleased to announce the launch of the first generic GLP-1 product in the U.S. marketplace and we hope that it will help improve access and address some of the current challenges,\u201d said a Teva spokesperson.<\/span><\/p>\n

https:\/\/www.investing.com\/news\/transcripts\/teva-at-goldman-sachs-conference-strategic-shift-to-biopharma-93CH-4088940<\/span><\/a><\/p>\n

\n
\n
\n
\n
\n
\n
\n
Goldman Sachs initiates coverage on Teva Pharmaceutical Industries (TEVA) with a “Buy” rating and a price target of $24.<\/span><\/div>\n<\/div>\n
\n
* **Initiation of Coverage:** Goldman Sachs is starting to formally research and provide recommendations on Teva Pharmaceutical Industries. This is the first time they are publicly expressing their opinion on the stock.<\/span><\/div>\n
* **Buy Rating:** This is a recommendation to purchase shares of Teva. [[1]](https:\/\/stockinvest.us\/stock\/TEVA<\/a><\/span>) Goldman Sachs believes that the stock is likely to perform well and increase in value. A “Buy” rating suggests that the analyst expects the stock to outperform its relevant benchmark in the near term. [[1]](https:\/\/stockinvest.us\/stock\/TEVA<\/a><\/span>)[[2]](https:\/\/www.goldmansachs.com\/…\/sales-and-trading-invest…<\/a><\/span>) Some firms may use ratings like “strong buy” or “outperform” which also suggest the analyst is favorable on the stock.<\/span><\/div>\n
* **Price Target of $24:** Goldman Sachs is predicting that the stock price of Teva will reach $24 within a specific timeframe, usually within 12 months. [[3]](https:\/\/www.gurufocus.com\/…\/goldman-sachs-favors-teva…<\/a><\/span>) This target price suggests a potential upside of 35.14% from the stock’s current price. [[4]](https:\/\/www.marketbeat.com\/…\/the-goldman-sachs-group…\/<\/a><\/span>)<\/span><\/div>\n<\/div>\n
\n
**Additional Considerations**<\/span><\/div>\n<\/div>\n
\n
* **Upside Potential:** The price target suggests that Goldman Sachs believes the stock is currently undervalued and has room to grow. [[5]](https:\/\/uk.investing.com\/…\/goldman-sachs-initiates-buy…<\/a><\/span>)<\/span><\/div>\n
* **Analyst Expectations:** Goldman Sachs analysts expect strong growth in Teva’s branded segment, including products like Austedo, Uzedy, and Ajovy. [[5]](https:\/\/uk.investing.com\/…\/goldman-sachs-initiates-buy…<\/a><\/span>) They also anticipate Teva’s restructuring and cost-cutting efforts to positively impact EBITDA estimates. [[5]](https:\/\/uk.investing.com\/…\/goldman-sachs-initiates-buy…<\/a><\/span>)<\/span><\/div>\n
* **Market Sentiment:** The initiation of coverage with a “Buy” rating can positively influence market sentiment towards Teva, potentially attracting more investors and driving up the stock price.<\/span><\/div>\n
* **Other Analyst Ratings:** It’s worth noting that other analysts have also issued positive ratings for Teva. The consensus recommendation from 11 brokerage firms is an average rating of 2.1, indicating an “Outperform” status. [[3]](https:\/\/www.gurufocus.com\/…\/goldman-sachs-favors-teva…<\/a><\/span>) The average price target from analysts is $24.13. [[6]](https:\/\/www.zacks.com\/…\/TEVA\/price-target-stock-forecast<\/a><\/span>)<\/span><\/div>\n
* **Financial Health:** InvestingPro data indicates that Teva has a “GOOD” overall financial health score, with particularly strong momentum metrics. [[5]](https:\/\/uk.investing.com\/…\/goldman-sachs-initiates-buy…<\/a><\/span>)<\/span><\/div>\n
Learn more:<\/span><\/strong><\/div>\n
1. [Teva Pharmaceutical Industries Limited Stock Forecast – StockInvest.us<\/a><\/span>](https:\/\/stockinvest.us\/stock\/TEVA<\/a><\/span>)<\/span><\/div>\n
2. [Goldman Sachs Global Banking & Markets MAR Investment Recommendation Disclosures](https:\/\/www.goldmansachs.com\/…\/sales-and-trading-invest…<\/a><\/span>)<\/span><\/div>\n
3. [Goldman Sachs Favors TEVA with Optimistic Growth Outlook – GuruFocus](https:\/\/www.gurufocus.com\/…\/goldman-sachs-favors-teva…<\/a><\/span>)<\/span><\/div>\n
4. [Teva Pharmaceutical Industries (NYSE:TEVA) Earns Buy Rating from Analysts at The Goldman Sachs Group – MarketBeat](https:\/\/www.marketbeat.com\/…\/the-goldman-sachs-group…\/<\/a><\/span>)<\/span><\/div>\n
5. [goldman sachs initiates buy rating on teva pharma stock – Investing.com<\/a><\/span> UK](https:\/\/uk.investing.com\/…\/goldman-sachs-initiates-buy…<\/a><\/span>)<\/span><\/div>\n
6. [What is the current Price Target and Forecast for Teva Pharmaceutical Industries (TEVA)](https:\/\/www.zacks.com\/…\/TEVA\/price-target-stock-forecast<\/a><\/span>)<\/span><\/div>\n
\n
\n

Previous Good News. Dec 17, 2024 2:50 PM Teva shares jump as its most promising drug shows exceptional trial results Duvakitug, designed to treat colitis and Crohn\u2019s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments. Teva entered into a co-development agreement with Sanofi about a year ago. Under the terms of the deal, Sanofi paid Teva $500 million upfront, with additional milestone-based payments of up to $1 billion. Teva will receive $600 million upon entering Phase 3 trials and another $400 million upon the drug\u2019s commercial launch. Development costs will be equally shared by both companies. This is a long-term endeavor: Phase 3 trials are not expected to begin before 2025, and the commercial launch of the drug is projected towards the end of the decade. If clinical trials are successful and the drug receives FDA approval, Teva and Sanofi will split the profits equally. Teva will be responsible for the drug\u2019s launch in Europe and Israel, while Sanofi will manage its commercialization in the U.S., Asia, and other global markets.<\/span><\/p>\n

\n

For more than a century, patients, caregivers and healthcare providers have used Teva medicines and products. As the global leader in generic medicine, nearly 200 million people across six continents take one of our products every day.<\/span><\/p>\n

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its main products include Copaxone, a specialty drug (for the treatment of multiple sclerosis), now the world’s best selling MS drug, Azilect (sold as Agilect in some countries) for treatment of Parkinson’s disease, and Provigil.<\/span><\/p>\n

Website:\u00a0 http:\/\/www.tevapharm.com<\/a><\/span><\/p>\n

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines.<\/span><\/p>\n

The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. <\/span><\/p>\n

Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas.<\/span><\/p>\n

<\/p>\n

\n
Track all markets on TradingView<\/span><\/a><\/div>\n